This website publishes administrative rules on their effective dates, as designated by the adopting state agencies, colleges, and
universities.
| Rule |
Rule 3701-3-01 | Definitions.
Effective:
September 16, 2016
As used in Chapter 3701-3 of the Administrative
Code: (A) "Antimicrobial"
means an agent that kills microorganisms or suppresses microorganism
multiplication or growth. (B) "Arthropod" means an organism of the phylum Arthropoda, such
as an insect, spider, mite or tick. (C) "Board of health" means the board of health of the city or
general health district established by section 3709.01 of the Revised Code, or
the authority having the duties of a board of health in any city as authorized
by section 3709.05 of the Revised Code. (D) "Bioterrorism" means the intentional use of any
microorganism, virus, infectious substance, or biological product that may be
engineered as a result of biotechnology, or any naturally occurring or
bioengineered component of a microorganism, virus, infectious substance, or
biological product, to cause death, disease, or other biological malfunction in
a human, animal, plant, or other living organism as a means of influencing the
conduct of government or intimidating or coercing a population. (E) "Child care center" means any private
home, institution, or public or private facility in which child care is
provided for one or more infants, toddlers, pre-school children, and school
children outside of school hours, during any part of the twenty-four hour day,
by persons other than the parents or legal guardians of the children in
care. (F) "Department" means the Ohio department of
health. (G) "Diarrhea" means three or more loose
stools in a twenty-four hour period. (H) "Director" means the director of health
or his or her designee. (I) "Endemic" means the constant presence of
a disease or infectious agent within a given geographic area. (J) "Epidemic" or "outbreak" means the
occurrence of cases of disease in numbers greater than expected in a particular
population or for a particular period of time. (K) "Exclude" means to bar from
participation. (L) "Event" means an important happening or occurrence that
results from an actual or suspected act of bioterrorism, epidemic or pandemic
disease, established or novel infectious agents, or biological or chemical
toxins. (M) "Food handler" means a person who
prepares or serves food intended for human consumption. (N) "Health care provider" means any person or government entity
that provides health care services to individuals. "Health care provider"
includes, but is not limited to, hospitals, medical clinics and offices,
special care facilities, medical laboratories, physicians, dentists, physician
assistants, registered and licensed practical nurses, emergency medical service
organization personnel, and ambulance service personnel. (O) "Health district" means a city or general
health district as created by Chapter 3709. of the Revised Code. (P) "Incidence" means the number of new cases
of a disease occurring during a specified interval of time in a defined
population. (Q) "Infected individual" means a person
whose body harbors a specific microorganism capable of producing disease,
whether or not the person is experiencing signs or symptoms of the
disease. (R) "Isolation"
means the separation of an infected individual from others during the period of
disease communicability in such a way that prevents, as far as possible, the
direct or indirect conveyance of an infectious agent to those who are
susceptible to infection or who may spread the agent to others. (S) "Pandemic"
means an epidemic disease that is occurring throughout a very wide area,
usually several countries or continents, and usually affecting a large
proportion of the population. (T) "Poison
prevention and treatment center" or "center" means an entity designated as a
poison prevention and treatment center by the director of health under section
3701.20 of the Revised Code. (U) "Period of
communicability" means the interval during which an infected individual or
animal is shedding the specific microorganism of a communicable disease in such
a manner that those who are susceptible could acquire the
infection. (V) Mammal means a
warm blooded animal, other than a human being, usually with hair, that gives
birth to live young, which are fed with milk secreted by the female mammary
gland. (W) "Quarantine"
means the restriction of the movements or activities of a well individual or
animal who has been exposed to a communicable disease during the period of
communicability of that disease and in such a manner that transmission of the
disease may have occurred. The duration of the quarantine ordered shall be
equivalent to the usual incubation period of the disease to which the
susceptible person or animal was exposed. (X) "Sensitive
occupation" means direct food handling, direct patient care, the handling of
food or provision of direct care to children in a child care center, or any
other occupation which provides significant opportunity for an infected
individual to transmit infectious disease agents. (Y) "Sexually-transmitted disease" or "venereal disease" is
an infectious disease commonly contracted through sexual contact such as
chancroid, chlamydia, gonococcal infection, granuloma inguinale, human
immunodeficiency virus infection, lymphogranuloma venereum, or
syphilis. (Z) "Surveillance"
means, in the public health service, the systematic collection, analysis,
interpretation, and dissemination, of health data on an on-going basis, to gain
knowledge of the pattern of disease occurrence and potential in a community in
order to control and prevent disease in the community. (AA) "Susceptible
person" means a person that, when exposed to an infectious microorganism, may
not possess sufficient resistance to prevent contracting the infection or
disease.
|
Rule 3701-3-02 | Diseases to be reported.
Effective:
August 1, 2019
The diseases listed in this rule and classified as
class "A,"class "B," and class "C" are declared
to be dangerous to the public health and are reportable. The occurrence of
cases or suspected cases of a disease classified as class "A," class
"B," or class "C" shall be reported, in detail, by health
care providers and laboratories to the board of health on forms as prescribed
and provided by the director and shall be reported in accordance with this rule
and Chapter 3701-3 of the Administrative Code. (A) Due to the severity of disease or the
potential for epidemic spread, diseases of major public health concern are
classified as class "A." The following diseases are classified as
class "A" and shall be reported immediately via telephone in
accordance with rules 3701-3-03, 3701-3-04, and 3701-3-05 of the Administrative
Code: (1) Anthrax; (2) Botulism,
foodborne; (3) Cholera; (4) Diphtheria; (5) Influenza
"A" - novel virus infection; (6) Measles; (7) Meningococcal
disease; (8) Middle east
respiratory syndrome (MERS); (9) Plague; (10) Rabies, human; (11) Rubella (not
congenital); (12) Severe acute respiratory syndrome
(SARS); (13) Smallpox; (14) Tularemia; (15) Viral hemorrhagic fever (VHF),
including Ebola virus disease, Lassa fever, Marburg hemorrhagic fever, and
Crimean-Congo hemorrhagic fever; and (16) Any unexpected pattern of cases,
suspected cases, deaths or increased incidence of any other disease of major
public health concern, because of the severity of disease or potential for
epidemic spread, which may indicate a newly recognized infectious agent,
outbreak, epidemic, related public health hazard or act of
bioterrorism. (B) Due to the potential for epidemic
spread, diseases of significant public health concern are classified as class
"B." The following diseases are classified as class "B" and
shall be reported in accordance with this rule and rules 3701-3-03, 3701-3-04,
and 3701-3-05 of the Administrative Code: (1) Amebiasis; (2) Arboviral neuroinvasive and
non-neuroinvasive diseases: (a) Chikungunya virus infection; (b) Eastern equine encephalitis virus disease; (c) LaCrosse virus disease (other California serogroup virus
disease); (d) Powassan virus disease; (e) St. Louis encephalitis virus disease; (f) West Nile virus infection; (g) Western equine encephalitis virus disease; (h) Yellow Fever; (i) Zika virus infection; (j) Other Arthopod-borne diseases; (3) Babesiosis; (4) Botulism; (a) Infant; (b) Wound; (5) Brucellosis; (6) Campylobacteriosis; (7) Candida
auris; (8) Carbapenemase-producing
carbapenem-resistant Enterobacteriaceae (CP-CRE): (a) CP-CRE Enterobacter spp.; (b) CP-CRE Escherichia coli; (c) CP-CRE Klebsiella spp.; (d) CP-CRE other; (9) Chancroid; (10) Chlamydia trachomatis
infections; (11) Coccidioidomycosis; (12) Creutzfeldt-Jakob disease
(CJD); (13) Cryptosporidiosis; (14) Cyclosporiasis; (15) Dengue; (16) E. coli O157:H7 and Shiga
toxin-producing E. coli (STEC); (17) Ehrlichiosis/anaplasmosis; (18) Giardiasis; (19) Gonorrhea (Neisseria
gonorrhoeae); (20) Haemophilus influenzae (invasive
disease); (21) Hantavirus; (22) Hemolytic uremic syndrome
(HUS); (23) Hepatitis A; (24) Hepatitis B
(non-perinatal); (25) Hepatitis B (perinatal); (26) Hepatitis C
(non-perinatal); (27) Hepatitis C (perinatal); (28) Hepatitis D (delta
hepatitis); (29) Hepatitis E; (30) Influenza-associated
hospitalization; (31) Influenza-associated pediatric
mortality; (32) Legionnaires'
disease; (33) Leprosy (Hansen
disease); (34) Leptospirosis; (35) Listeriosis; (36) Lyme disease; (37) Malaria; (38) Meningitis: (a) Aseptic (viral); (b) Bacterial; (39) Mumps; (40) Pertussis; (41) Poliomyelitis (including
vaccine-associated cases); (42) Psittacosis; (43) Q fever; (44) Rubella (congenital); (45) Salmonella Paratyphi
infection; (46) Salmonella Typhi
infection (typhoid fever); (47) Salmonellosis; (48) Shigellosis; (49) Spotted Fever Rickettsiosis,
including Rocky Mountain spotted fever (RMSF); (50) Staphylococcus aureus, with
resistance or intermediate resistance to vancomycin (VRSA, VISA); (51) Streptococcal disease, group A,
invasive (IGAS); (52) Streptococcal disease, group B, in
newborn; (53) Streptococcal toxic shock syndrome
(STSS); (54) Streptococcus pneumoniae, invasive
disease (ISP); (55) Syphilis; (56) Tetanus; (57) Toxic shock syndrome
(TSS); (58) Trichinellosis; (59) Tuberculosis (TB), including
multi-drug resistant tuberculosis (MDR-TB); (60) Varicella; (61) Vibriosis; and (62) Yersiniosis. (C) The following are classified as class
"C" and shall be reported by the end of the next business day in
accordance with this rule and rules 3701-3-03, 3701-3-04, and 3701-3-05 of the
Administrative Code unless paragraph (C)(7) of this rule applies - outbreak,
unusual incidence, or epidemic of other infectious diseases from the following
sources: (1) Community; (2) Foodborne; (3) Healthcare-associated; (4) Institutional; (5) Waterborne;
and (6) Zoonotic; (7) If the outbreak,
unusual incidence, or epidemic, including but not limited to, histoplasmosis,
pediculosis, scabies, and staphylococcal infections, has an unexpected pattern
of cases, suspected cases, deaths, or increased incidence of disease that is of
a major public health concern pursuant to paragraph (A)(16) of this rule, then
such outbreak, unusual incidence, or epidemic shall be reported in accordance
with paragraph (A) of rule 3701-3-05 of the Administrative Code.
|
Rule 3701-3-02.1 | Reporting of occupational diseases.
(A) Every physician attending on or called in to visit a patient whom the physician believes to be suffering from any of the occupational diseases or occupationally related ailments listed in paragraph (B) of this rule shall submit a report to the director of health within forty-eight hours from the time of first attending the patient. This report shall be made on, or in conformity with, the standard schedule blanks which the director is required to provide physicians pursuant to section 3701.26 of the Revised Code and shall contain the following information: (1) The name, address, and occupation of the patient; (2) The name, address, and business of the patient's employer; (3) The nature of the disease or ailment; and (4) Name, address and telephone number of the physician. The mailing of the report, within the time required by this paragraph shall constitute compliance with section 3701.25 the Revised Code and this rule. (B) The following occupational diseases and ailments are required to be reported: (1) Poisoning from phosphorous, brass, arsenic, mercury, wood alcohol or their compounds; (2) Compressed air illness; (3) Poisoning from lead and cadmium.
|
Rule 3701-3-02.2 | Air- and blood-borne diseases reasonably likely to be transmitted to emergency medical services workers.
(A) Section 3701.248 of the Revised Code allows an emergency medical services worker to ask a health care facility or coroner to notify them of the results of tests for certain diseases, if the worker believes that he or she had a significant exposure through contact with a patient. The diseases subject to this procedure are contagious or infectious diseases that are specified as reasonably likely to be transmitted by air or blood during the normal course of an emergency medical services worker's duties. The diseases listed in paragraph (B) of this rule are specified for purposes of section 3701.248 of the Revised Code. (B) The following diseases are specified as reasonably likely to be transmitted by air or blood during the normal course of an emergency medical worker's duties: (1) Crimean-Congo hemorrhagic fever; (2) Diphtheria; (3) Ebola hemorrhagic fever; (4) Fifth disease (human parvovirus infection); (5) Hansen disease (leprosy); (6) Acute or chronic infection with hepatitis B virus; (7) Acute or chronic infection with hepatitis C virus; (8) Infection with hepatitis D virus (delta hepatitis); (9) Human immunodeficiency virus (HIV) infection, including acquired immunodeficiency syndrome (AIDS); (10) Infection with human t-lymphotropic virus (HTLV-1 and HTLV-2); (11) Lassa fever; (12) Leishmaniasis, visceral (Kala-Azar); (13) Leptospirosis; (14) Marburg hemorrhagic fever; (15) Measles (rubeola); (16) Meningococcal disease (Neisseria meningitidis); (17) Mumps (infectious parotitis); (18) Pertussis (whooping cough); (19) Pneumonic plague (Yersinia pestis); (20) Rabies; (21) Rubella (German measles); (22) Severe acute respiratory syndrome (SARS) (23) Tuberculosis; and (24) Varicella (herpes zoster) infection, including chickenpox and shingles.
|
Rule 3701-3-03 | Reportable disease notification.
Effective:
September 16, 2016
(A) A health care provider with knowledge of a case or
suspect case of a disease which is required by law to be reported, including
all class "A", class "B", and class "C" categories of disease designated as
reportable under rule 3701-3-02 of the Administrative Code, shall submit a case
report in the manner set forth in rule 3701-3-05 of the Administrative
Code. (1) A health care provider may submit electronic reports in
the manner approved by the director. (2) Unless otherwise demonstrated, a health care provider
who submits electronic reports in the manner approved by the director shall be
presumed compliant with section 3701.23 of the Revised Code and rules
3701-3-02, 3701-3-04, and 3701-3-05 of the Administrative Code. (B) Reports of cases and suspect cases shall include, but
not limited to, the following: (1) Case or suspect case information: name, diagnosis or
suspected diagnosis, date of birth, sex, telephone number, and street address
including city, state, and zip code. (2) Health care provider information: name, telephone
number, and street address including city, state, and zip code. (3) Supplementary information as needed to complete
official surveillance forms provided or set forth by the director. (C) Any individual having knowledge of a person suffering
from a disease suspected of being communicable is authorized to report to
public health authorities all known facts relating to the case or
incident.
|
Rule 3701-3-04 | Laboratory result reporting.
Effective:
September 16, 2016
(A) The person in charge of any laboratory that examines
specimens of human origin for evidence of diseases designated as reportable by
rule 3701-3-02 of the Administrative Code shall report all positive results of
such examinations in the manner set forth in rule 3701-3-05 of the
Administrative Code. (B) A positive result of a laboratory examination for a
reportable disease shall be considered reason to suspect that a person is
infected by that disease. Upon receipt of a laboratory report of a positive
result for a reportable disease, the city or general health district in which
the suspect case resides shall make an inquiry through the appropriate health
care provider to determine if the suspected case exists. (C) A laboratory report shall include, but not be limited
to, the following: (1) Case information: name, date of birth, sex, and street
address including city, state, and zip code. (2) Laboratory test information: specimen identification
number, specimen collection date, specimen type, test name, test result, and if
applicable, the organism and serotype. (3) Health care provider information: name, telephone
number, street address including city, state, and postal zip code.
|
Rule 3701-3-05 | Time to report.
Effective:
September 16, 2016
Reports by health care providers, as specified in
rule 3701-3-03 of the Administrative Code, and reports by laboratories of
positive results, as specified in rule 3701-3-04 of the Administrative Code,
shall be provided in the manner set forth by the director according to the
following time and method of reporting: (A) Cases, suspect cases, and positive
laboratory results for diseases specified as class "A" in paragraph
(A) of rule 3701-3-02 of the Administrative Code shall be initially and
immediately provided by telephone to the local health jurisdiction in which the
case or suspected case resides, or if the residence is unknown, to the Ohio
department of health. Follow up reports shall be provided in the manner set
forth by the director. If cases, suspect cases, and positive laboratory results
for diseases specified as class "A" are reported to a local health
district, such local health jurisdiction shall immediately notify the Ohio
department of health in the manner set forth by the director. (B) Case and suspect case reports and
reports of positive laboratory results for diseases specified as class
"B"in paragraph (B) of rule 3701-3-02 of the Administrative Code
shall be provided by the end of the next business day. (C) Reports related to an actual or
suspected outbreak, unusual incident, or epidemic of any disease specified as
class "C" in paragraph (C) of rule 3701-3-02 of the Administrative
Code shall be provided by the end of the next business day, unless the
unexpected pattern of cases, suspect cases, deaths, or increased incidence of
disease is of major public health concern pursuant to paragraph (A) of rule
3701-3-02 of the Administrative Code, then such reports shall be made according
to paragraph (A) of this rule.
|
Rule 3701-3-06 | Reporting to department.
Effective:
September 16, 2016
A board of health that receives a report of a case,
suspected case or positive laboratory result pursuant to rules 3701-3-02,
3701-3-03, 3701-3-04, and 3701-3-05 of the Administrative Code shall report the
same report to the department as follows: (A) Diseases specified as class
"A" in paragraph (A) of rule 3701-3-02 of the Administrative Code
shall be reported by telephone immediately after the existence of such case or
suspect case is known to the board of health. (B) Diseases specified as class
"B"in paragraph (B) of rule 3701-3-02 of the Administrative Code
shall be reported by the end of the next business day after the existence of
such case or suspect case or positive laboratory result is known to the board
of health. (C) Outbreaks, unusual incidence, or
epidemics of diseases specified as class "C" in paragraph (C) of rule
3701-3-02 of the Administrative Code shall be reported by the end of the next
business day after the outbreak, unusual incidence, or epidemic is known to the
board of health.
|
Rule 3701-3-08 | Release of patient's medical records.
Any person, hospital, clinic, agency or other institution or facility providing care or treatment to an individual suffering from a communicable disease which is required to be reported under Chapter 3701. of the Revised Code and the rules adopted by the director of health, or a disease that the director requires special inquiry be made under sections 3701.13 and 3701.14 of the Revised Code, shall, upon written request by the director provide access to the patient's medical record to the director during an investigation of such disease.
|
Rule 3701-3-10 | Approval of human immunodeficiency virus tests.
(A) In approving tests to be used to determine whether an individual has human immunodeficiency virus infection under division (B)(1) of section 3701.241 of the Revised Code, the director of health shall consider: (1) Whether the test has been approved by the United States food and drug administration. (2) The recommendations of the United States centers for disease control and prevention. (B) The director shall define a confirmed positive test result as: (1) Two or more reactive enzyme immunoassay tests; (2) A positive culture of the human immunodeficiency virus; (3) A positive reaction to an human immunodeficiency virus antigen test licensed by the United States food and drug administration; (4) Identification of the human immunodeficiency virus by the use of nucleic acid amplification probe to detect the presence of human immunodeficiency virus; (5) The director may define other confirmed positive test results after consideration of the recommendations of the United States centers for disease control and prevention. (C) In developing guidelines for interpreting test results, the director shall consider interpretation criteria established by the United States centers for disease control and prevention.
|
Rule 3701-3-11 | Requirements related to human immunodeficiency virus testing.
Effective:
October 30, 2010
(A) A human immunodeficiency virus (HIV) test may be performed by or on the order of the health care provider who, in the exercise of the provider's professional judgment and within the provider's scope of practice, determines the test to be necessary for providing diagnosis and treatment to the individual to be tested if the individual or the individual's parent or guardian has given consent. Prior to performing or ordering an HIV test, the health care provider shall inform the individual to be tested of the individual's right to an anonymous test as set forth in section 3701.242 of the Revised Code and paragraph (C) of this rule. (B) Pursuant to division (B) of section 3701.242 of the Revised Code, a minor may consent to be given an HIV test. The consent is not subject to disaffirmance because of minority. The parents or guardian of a minor giving consent under this paragraph are not responsible for payments for an HIV test given to the minor without the consent of a parent or the guardian. (C) Any individual seeking an HIV test shall have the right, on the individual's request, to an anonymous test. A health care facility or health care provider that does not provide anonymous testing shall refer the individual requesting an anonymous test to a site where anonymous testing is available. (D) If an individual tests positive for HIV, the health care provider who performed or ordered the test shall provide post-test counseling. Post-test counseling is suggested for all individuals seeking testing. Post-test counseling may be verbal or in writing and shall included, but is not limited to, the following: (1) An explanation of the HIV test result. If, at the time of the HIV test, the result is preliminarily positive, the health care provider must explain the next step to confirm the test result; (2) The nature of HIV disease; (3) A list of resources for medical treatment, social services and, when necessary, a referral for further counseling to help that individual cope with the emotional consequences of learning of the test result; (4) The individual will be provided information about the importance of following safer sex practices to protect themselves from sexually transmitted diseases, as well as how to protect others from being infected; and (5) The individual will be provided information about Ohio's HIV disclosure laws. (E) The requirements of paragraphs (B) to (D) of this rule do not apply to the performance of an HIV test in any of the following circumstances: (1) When the test is performed in a medical emergency by a nurse or physician and the test results are medically necessary to avoid or minimize an immediate danger to the health or safety of the individual to be tested or another individual. Post-test counseling shall be given to the individual if the individual received an HIV positive test result as soon as possible after the emergency is over; (2) When the test is performed for the purpose of research if the researcher does not know and cannot determine the identity of the individual tested; (3) When the test is performed by a person who procures, processes, distributes, or uses a human body part from deceased person donated for a purpose specified in Chapter 2108. of the Revised Code, if the test is medically necessary to ensure that the body part is acceptable for its intended purpose; (4) When the test is performed on a person incarcerated in a penal institution if the head of the institution has determined, based on good cause, that a test is necessary; or (5) When the test is performed on an individual after the infection control committee of a health care facility, or other body of a health care facility performing a similar function determines that a health care provider, emergency medical service worker, or peace officer, when rendering health or emergency care to an individual, has sustained significant exposure to the body fluids that are known to transmit HIV of that individual, and the individual has refused to give consent for testing. (F) The consent of the individual to be tested is not required, and the individual or guardian may not elect to have an anonymous test, when the test is ordered by a court in connection with a criminal investigation.
|
Rule 3701-3-12 | AIDS, ARC, and HIV test reporting.
(A) As used in this rule: (1) "AIDS" has the same meaning as in section 3701.24 of the Revised Code. (2) "ARC" is a historic term having the same meaning as in section 3701.24 of the Revised Code. (3) "A CD4 count" means a count of lymphocytes containing the CD4 epitope as determined by the results of lymphocyte phenotyping. (4) "Health care facility" has the same meaning as in section 3701.24 of the Revised Code. (5) "Health care provider" has the same meaning as in section 3701.23 of the Revised Code. (6) "HIV" has the same meaning as in section 3701.24 of the Revised Code. (7) "HIV infection" means a disease of the human immune system caused by infection with the human immunodeficiency virus. (8) "HIV test" has the same meaning as in section 3701.24 of the Revised Code. (9) "HIV viral load" means concentration of HIV virus in blood. (B) Persons required to report cases of AIDS, ARC, HIV, confirmed positive tests for HIV, and HIV infections pursuant to divisions (B) and (C) of section 3701.24 of the Revised Code and this rule are as follows: (1) Health care providers shall report every case of HIV infection, including AIDS, for persons under their treatment and care. In an institutional or health care facility setting, a designated agent, including, but not limited to, an infection preventionist may make the report for the diagnosing or treating health care provider. (2) The individual in charge of the laboratory shall report all positive or repeatedly reactive results from antigen detection, nucleic acid detection, detection of antibody confirmed with a supplemental test, or positive cultures used in the diagnosis of HIV infection, CD4 counts and percentages when performed to monitor the progression of HIV disease, and detectable and undetectable viral load results when performed to monitor the efficacy of HIV treatment. If a second laboratory is used for additional or supplemental HIV testing, the person in charge of the laboratory first receiving the specimen shall report the results of the supplemental testing. (C) Every health care provider attending a newborn infant or child born to an HIV infected mother shall report every instance of perinatal exposure to HIV and any subsequent test results on every such exposed newborn infant or child until such time that either an HIV infection or a sero status that is negative is confirmed. In an institutional or health care facility setting, a designated agent, including, but not limited to, an infection preventionist, may make the report for the diagnosing or treating health care provider. (D) Persons designated by paragraphs (B) and (C) of this rule shall report every case of HIV infection, including AIDS, every instance of perinatal exposure to HIV, and HIV test as described in paragraph (B)(2) of this rule to the department of health as follows (in each county the director shall designate the health commissioner of a health district in the county to receive the reports): (1) Health care provider shall provide the following information: (a) Case information: name, diagnosis, date of birth, sex, ethnicity, race, and street address including city, state, and zip code. (b) Health care provider information: name, telephone number, and street address including city, state, and zip code. (c) Laboratory test information: specimen collection date, specimen type, test name, test result, and reference range, where applicable. (d) Supplementary information as needed to complete official surveillance forms provided or set forth by the director. (e) A health care provider may submit electronic reports in the manner approved by the director. (2) Person in charge of a laboratory shall provide the following information: (a) Case information: name, diagnosis, date of birth, sex, ethnicity, race, and street address including city, state, and zip code. (b) Health care provider information: name, telephone number, and street address including city, state, and zip code. (c) Laboratory information: name, telephone number, and street address including city, state, and zip code. (d) Laboratory test information: specimen collection date, specimen type, test name, test result, and reference range, where applicable. (e) A laboratory may submit electronic reports in the manner approved by the director. (3) Health care providers and laboratories shall report in the following manner: (a) Persons designated in paragph (B)(1) of this rule shall report to the local health district in which the case resides, or if the residence is unknown, to the Ohio department of health no later five calendar days from the date of diagnosis or specimen collection date, whichever is later. (b) Persons designated in paragraph (B)(2) of this rule shall report to the local health district in which the case resides, or if the residence is unknown, to the Ohio department of health no later than five calendar days from the test result. (c) Persons designated in paragraph (C) of this rule shall report to the local health district in which the infant was born, or if unknown, to the Ohio department of health no later than five calendar days from the infant's date of birth.
|
Rule 3701-3-13 | Isolation requirement.
A person infected with one of the following specified diseases or conditions shall be isolated as set forth in this rule: (A) Amebiasis: a person with amebiasis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return after diarrhea has ceased and three follow-up stool specimens are negative for Entamoeba histolytica. (B) Campylobacteriosis: a person with campylobacteriosis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return when the following conditions are met: (1) A child may return to a child care center after his or her diarrhea has ceased. (2) A person may return to work in a sensitive occupation after diarrhea has ceased, provided the person's duties do not include food handling. (3) A food handler may return to work only after diarrhea has ceased and one of the following conditions are met: (a) Forty-eight hours of effective antimicrobial therapy; or (b) Two consecutive follow-up stool specimens are negative for Campylobacter. (C) Chickenpox: a person with chickenpox shall be isolated, including exclusion from school, child care center, and public places until the sixth day after onset of rash, or until all lesions are dry. Contagiousness may be prolonged in patients with altered immunity. Persons with chickenpox shall avoid contact with susceptible persons. (D) Cholera: a person with cholera who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return when the following conditions are met: (1) A child may return to a child care center after diarrhea has ceased. (2) A person may return to work in a sensitive occupation after diarrhea has ceased, provided that his or her duties do not include food handling. (3) A food handler may return to work after diarrhea has ceased and two consecutive follow-up stool specimens are negative for Vibrio cholerae. (E) Conjunctivitis, purulent: a person with purulent conjunctivitis who attends or works in a child care center shall be excluded from the child care center and may return twenty-four hours after the initiation of effective antimicrobial therapy. (F) Cryptosporidiosis: a person with cryptosporidiosis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return when the following conditions are met: (1) The child may return to the child care center after diarrhea has ceased. (2) A person may return to work in a sensitive occupation after diarrhea has ceased, provided that his or her duties do not include food handling. (3) A food handler may return to work after diarrhea has ceased and after three consecutive follow-up stool specimens are negative for Cryptosporidium. (G) Cyclosporiasis: a person with cyclosporiasis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return after diarrhea has ceased and effective antimicrobial therapy has begun. (H) Diarrhea, infectious or of unknown cause: a person with diarrhea, of infectious or unknown cause, who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return only after diarrhea has ceased. A person with infectious diarrhea of known cause shall be isolated in accordance with the provisions of the rule set forth for the specified disease. (I) Diphtheria: a person with diphtheria shall be isolated until two cultures, from both throat and nose, and additionally, in the case of cutaneous diphtheria, a culture from skin lesions, are negative for diphtheria bacilli. Cultures shall be taken not less than twenty-four hours apart, and not less than twenty-four hours after cessation of antimicrobial therapy. If culturing is unavailable or impractical, isolation may be ended after fourteen days of effective antimicrobial therapy. (J) Escherichia coli (E. coli) O157:H7, other enterohemorrhagic (Shiga toxin-producing) E. coli or hemolytic uremic syndrome (HUS): a person with Escherichia coli (E. coli) O157:H7, other enterohemorrhagic (Shiga toxin-producing) E. coli or hemolytic uremic syndrome (HUS) who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return after his or her diarrhea has ceased and after two consecutive follow-up stool specimens are negative for E. coli O157:H7 or other enterohemorrhagic (Shiga toxin-producing) E. coli. (K) Giardiasis: a person with giardiasis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return after diarrhea has ceased and one of the following conditions have been met: (1) Seventy-two hours of effective antimicrobial therapy; or (2) Three consecutive follow-up stool specimens are negative for Giardia. (L) Hepatitis A: a person with hepatitis A who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation until ten days after initial onset of symptoms. (M) Measles: a person with measles shall be isolated, including exclusion from school or child care center, for four days following the onset of rash. Contagiousness may be prolonged in patients with altered immunity. (N) Meningitis, aseptic, and viral meningoencephalitis, but not including arthropod-borne disease: a person with aseptic meningitis or viral meningoencephalitis shall be excluded from school or child care center until he or she is afebrile. (O) Meningococcal disease: a person with meningococcal disease shall be isolated until twenty-four hours after the initiation of effective antimicrobial therapy. (P) Mumps: a person with mumps shall be isolated, including exclusion from school or child care center, for five days after the onset of parotid swelling. (Q) Pediculosis: a person with body lice shall be excluded from school or child care center until twenty-four hours after application of an effective pediculicide. A person with head lice shall be excluded from school or child care center until after the first treatment with an effective pediculicide. (R) Pertussis (whooping cough): a person with pertussis, who is not treated with effective antimicrobial therapy, shall be isolated, including exclusion from school or child care center, until three weeks after the onset of paroxysms. If effective antimicrobial therapy is given, the person shall be isolated for five days after initiation of antimicrobial therapy. (S) Plague: a person with plague shall be placed in droplet isolation until completion of forty-eight hours of effective antimicrobial therapy. (T) Rubella: a person with rubella shall be isolated, including exclusion from school or child care center, for seven days after the onset of the rash. Persons with congenital rubella shall be isolated until they are one year old unless nasopharyngeal and urine cultures after three months of age are repeatedly negative for rubella. (U) Salmonellosis: a person with salmonellosis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return when the following conditions are met: (1) The child may return to the child care center after diarrhea has ceased. (2) A person may return to work in a sensitive occupation after diarrhea has ceased, provided that his or her duties do not include food handling. (3) A person who is a food handler may return to work after diarrhea has ceased and after two consecutive follow-up stool specimens are negative for Salmonella. (V) SARS (severe acute respiratory distress syndrome): a person with confirmed or suspected SARS shall be placed in airborne isolation until no longer considered infectious. (W) Scabies: a person with scabies shall be isolated for twenty-four hours following initial treatment with an effective scabicide. A person with the manifestation of scabies known as "crusted scabies" shall be isolated until the mite can no longer be demonstrated on a scabies preparation. (X) Shigellosis: a person with shigellosis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return if diarrhea has ceased and after two consecutive follow-up stool specimens are negative for Shigella. (Y) Smallpox: a person with confirmed or suspected smallpox shall be placed in airborne isolation in a facility designated by the director. The patient's release from the facility can occur when all scabs have fallen off. (Z) Streptococcal infection: a person with a streptococcal infection shall be excluded from school or child care center for twenty-four hours after the initiation of effective antimicrobial therapy. (AA) Tuberculosis (TB): a person with infectious tuberculosis shall be isolated according to Chapter 3701-15 of the Administrative Code until the person has three negative AFB sputum smear results, collected eight to twenty-four hours apart (with at least one being an early morning specimen) and the person has responded clinically to an antituberculosis treatment regimen consistent with the results of any susceptibility testing performed and until the local authorized TB authority, as set out in section 339.72 of the Revised Code, or his or her designee approves that person's removal from isolation. (BB) Typhoid fever person works in a sensitive occupation shall be excluded from work and may return after the person is asymptomatic and after three consecutive follow-up stool specimens are negative for Salmonella Typhi. (CC) Typhus: a louse infested person with typhus shall be isolated until twenty-four hours after application of an effective pediculicide for body lice and clothing and environment are free of body lice. (DD) Viral hemorrhagic fever (VHF): a person with confirmed or suspected viral hemorrhagic fever shall be placed in airborne isolation until no longer considered infectious. (EE) Yellow fever: a person with confirmed or suspected yellow fever shall be isolated to prevent access of mosquitoes to the patient for at least five days after onset of disease. (FF) Yersiniosis: a person with yersiniosis who attends a child care center or works in a sensitive occupation shall be excluded from the child care center or work in the sensitive occupation and may return when the following conditions are met: (1) A child may return to the child care center after diarrhea has ceased. (2) A person may return to work in a sensitive occupation after diarrhea has ceased, provided that his or her duties do not include food handling. (3) A food handler may return to work after diarrhea has ceased and two consecutive follow-up stool specimens are negative for Yersinia.
|
Rule 3701-3-14 | Reporting requirements--poison control prevention and treatment centers and other health-related entities.
Effective:
November 1, 2015
(A) For the purpose of this rule (1) "Biological or chemical toxins" mean poisonous compounds produced by a microorganism or a poisonous chemical compound that pose a risk of human fatality or disability. (2) "Novel infectious agents" mean agents that are unusual that pose a risk of human fatality or disability. (3) "Other health-related entity" means an entity that employs health care providers, but that does not have an obligation to report events to the health district having jurisdiction in accordance with the requirements of Chapters 3701. and 3707. of the Revised Code. (B) A poison control prevention and treatment center or other health-related entity shall report the following events: (1) An unexpected pattern or increase in the number of telephone inquiries or requests to provide information about poison prevention and treatment and available services; (2) An unexpected pattern or increase in the number of requests to provide specialized treatment, consultation, information, and educational programs to health care professionals and the public; (3) An unexpected pattern or increase in the number of requests for information on established or novel infectious agents or biological or chemical toxins posing a risk of human fatality or disability that is relatively uncommon and may have been caused by bioterrorism. (C) Unless provided otherwise, all reports required by paragraph (B) of this rule shall be submitted to both the Ohio department of health and the health commissioner of the health district having jurisdiction over the event. Poison control prevention and treatment centers and other health-related entities shall immediately report an event as specified in rule 3701-3-02 of the Administrative Code, to the extent known or suspected, or upon the request from the director in the manner specified in paragraph (B) of rule 3701-3-03 of the Administrative Code. (D) As required by division (C) of section 3701.201 of the Revised Code, poison control prevention and treatment centers and other health-related entities shall report information regarding events as specified in this rule.
|
Rule 3701-3-15 | Reporting Requirements-Pharmacies or Pharmacists.
(A) As used in this rule: (1) "Pharmacist" means an individual licensed under Chapter 4729. of the Revised Code to engage in the practice of pharmacy as a pharmacist. (2) "Pharmacy," means the same as defined in division (A) of section 4729.01. of the Revised Code. (3) "Prescription" means the same as defined in division (H) of section 4729.01. of the Revised Code. (4) "Significant changes" means observations or occurrences of or related to medication usage that is, based on professional experience and judgment, too closely correlated to be attributed to chance. (5) "Unexpected increase" means, based on past experience, an unforeseen change in the types, urgency, or volume of sales, inquiries or requests specified in this rule. (B) All pharmacies and pharmacists shall immediately report information by telephone or electronically to the health commissioner of the health district having jurisdiction: (1) Any prescription for medication used to treat a disease that is relatively uncommon and may have been caused by bioterrorism, or (2) Significant changes in medication usage that may be caused by bioterrorism, epidemic or pandemic disease, or established or novel infectious agents or biological toxins posing a risk of human fatality or disability, or (3) An unexpected increase in: (a) The number of prescriptions issued for antibiotics; (b) The number of prescriptions issued for medications to treat fever or respiratory or gastrointestinal complaints; (c) The sales of or the number of requests for over-the-counter medication to treat fever, respiratory, or gastrointestinal complaints. (C) Pharmacies and pharmacists shall submit reports required by this rule using forms and formats approved by the director. A pharmacy or pharmacist using an electronic reporting system or systems, to the extent approved by the director, is deemed to comply with the reporting requirements of this rule until such use is no longer considered active by the director. (D) All health commissioners shall immediately report information received from pharmacies or pharmacists to the director. (1) Health commissioner reports shall be submitted by telephone or by electronic means approved by the director. (2) If a pharmacy has submitted an electronic report for over the counter medication sales as authorized by this rule and so advises the health commissioner, no further report is required. (E) Upon receipt of a request from a health commissioner of the health district having jurisdiction, each pharmacy in the jurisdiction and for each location within the jurisdiction shall: (1) Within ten business days of receiving such a request, identify an employee or employees of the pharmacy or a pharmacist or pharmacists employed at the pharmacy of who will be the point of contact for purposes of this rule. (2) Within ten business days advise the health commissioner having jurisdiction of any change in the information of who will be responsible for being the point of contact for purposes of this rule. (F) In consultation with the Ohio board of pharmacy, the director may publish a list of antibiotics and other medications that are required to be included in reports of significant changes in medication usage required by this rule. (G) A pharmacy or pharmacist shall report information regarding events as specified in this rule. A pharmacy or pharmacist that does not report events in compliance with this rule is subject to an administrative fine as specified in rule 3701-73-02 of the Administrative Code.
|
Rule 3701-3-16 | Reporting Drug Overdose.
(A) As used in this rule: (1) "Dedicated emergency department" means any
department or facility of a hospital, regardless of whether it is located on or
off the main hospital campus, which meets at least one of the following
requirements: (a) It is held out to the
public (by name, posted signs, advertising, or other means) as a place that
provides care for emergency medical conditions on an urgent basis without
requiring a previously scheduled appointment; or (b) During the calendar
year immediately preceding the calendar year in which a determination under
this rule is being made, based on a representative sample of patient visits
that occurred during that calendar year, it provides at least one-third of all
its outpatient visits for the treatment of emergency medical conditions on an
urgent basis without requiring a previously scheduled appointment. (2) "Drug overdose" means a patient diagnosed
with a nonfatal poisoning as set forth in appendix A to this rule. (B) A
dedicated emergency department is to report drug overdoses as set forth by the
director in appendix A to this rule within two business days of diagnosis. A
third-party organization may report as described in this rule on behalf of a
dedicated emergency department. (C) A
dedicated emergency department, or a third-party organization on behalf of the
dedicated emergency department, is to submit reports required by paragraph (B)
of this rule using forms and formats approved by the director. A dedicated
emergency department using an electronic reporting system or systems, including
third-party system reporting on behalf of a dedicated emergency department, to
the extent approved by the director, is deemed to comply with the reporting
requirements of this rule. (D) Information reported pursuant to this rule is protected
health information subject to section 3701.17 of the Revised Code.
Last updated April 8, 2024 at 8:29 AM
|
Rule 3701-3-28 | Report of bite of dog or other mammal.
Effective:
August 1, 2024
(A) Whenever an individual is bitten by a
dog or other non-human mammal, report of such bite will be made within
twenty-four hours to the health commissioner of the district in which such bite
occurred. The report herein required is to be made by any health care provider,
or by any licensed doctor of veterinary medicine with knowledge of the bite, or
by the individual bitten. (B) Local health districts are required
to submit information regarding non-human mammalian bites occurring in their
district to the Ohio department of health annually. This report for non-human
mammalian bites occurring in the previous calendar year is to be submitted by
March first.
Last updated August 1, 2024 at 7:55 AM
|
Rule 3701-3-29 | Biting animal to be confined; veterinarian to report.
Effective:
August 1, 2024
(A) Biting dog, cat, or
ferret. (1) Whenever it is
reported to the health commissioner of a health district that any dog, cat, or
ferret has bitten or otherwise exposed an individual to rabies, that dog, cat,
or ferret will be quarantined under an order issued by the health commissioner
of the health district in which the bite or exposure occurred. (a) The dog, cat, or ferret will be quarantined by its owner or
by a harborer, or will be quarantined in a pound, shelter, or
kennel. (b) In all cases, said quarantine will be under the supervision
of the health commissioner and is to be at the expense of the owner or
harborer. (c) Any sign of illness in the quarantined dog, cat or ferret
must be reported immediately to the health commissioner. (d) Quarantine will continue until the health commissioner of the
health district in which the bite was inflicted determines pursuant to
paragraph (A)(1)(f) of this rule that the dog, cat, or ferret is not afflicted
with rabies. (e) The quarantine period hereby required is to be not be less
than ten days from the date on which the person was bitten. (f) If at any time during the quarantine, the health commissioner
requires the dog, cat, or ferret to be examined for symptoms of rabies, then
the examination will be by a licensed doctor of veterinary medicine. The
licensed doctor of veterinary medicine will report to the health commissioner
the conclusions reached as a result of the examinations. The examination by a
licensed doctor of veterinary medicine is to be at the expense of the owner or
harborer. (g) No dog, cat, or ferret is to be released from the required
quarantine unless and until it has a current rabies vaccination status as
demonstrated by a rabies vaccination certificate signed by a licensed doctor of
veterinary medicine. (2) If any quarantined
dog, cat, or ferret dies before the quarantine period expires, then the head of
the dog, cat, or ferret must be submitted to the Ohio department of
health's bureau of public health laboratory for rabies
examination. (3) If the owner or
harborer of the dog, cat, or ferret is unknown, the health commissioner may
direct that the dog, cat, or ferret be humanely euthanized in which case the
head of the dog, cat, or ferret is to be submitted to the Ohio department of
health's bureau of public health laboratory for rabies
examination. (B) Other biting mammals including
hybrids. (1) Whenever it is
reported to the health commissioner of the health district that any other
mammal that is known to transmit rabies has bitten or otherwise exposed an
individual to rabies, under an order issued by the health commissioner of the
health district in which the bite or exposure occurred, the health commissioner
may direct the immediate humane euthanasia of said mammal by a. (2) The brain of said
mammal is to then be submitted to the Ohio department of health's bureau
of public health laboratory for rabies examination. (C) Any non-human mammal bitten by a
known rabid mammal, or that had reasonable probability to have been bitten by a
wild carnivorous mammal or bat that is not available for rabies testing will be
regarded as having been exposed to the rabies virus. (1) Dogs, cats, ferrets
not currently vaccinated against the rabies virus or when vaccination cannot be
verified will be humanely euthanized; or if sufficient justification for
preserving the animal exists, the exposed dog, cat, ferret will be quarantined
in strict isolation under an order issued by the health commissioner of the
health district in which the bite was inflicted. Isolation in this context
refers to confinement in an enclosure that precludes direct contact with people
and other animals. (a) In all cases, said quarantine will be under the supervision
of the health commissioner and is to be at the expense of the owner or
harborer. Any signs of illness in the dog, cat, or ferret must be reported
immediately to the health commissioner. (b) The quarantine period will not be for less than four months
for dogs and cats, and not less than six months for ferrets. The dog, cat, or
ferret is to be vaccinated against rabies by a licensed doctor of veterinary
medicine upon entry into quarantine. It is recommended that the period from
exposure to vaccination not exceed ninety-six hours. If vaccination is delayed,
public health officials may consider increasing the quarantine period for dogs
and cats from four to six months. (2) A rabies vaccine
booster is to be administered immediately and the mammal quarantined under an
order issued by the health commissioner of the health district in which the
bite was inflicted under the following circumstances: mammals with a current
rabies vaccination, dogs and cats overdue for rabies vaccination with
documentation of previous vaccination(s) with a USDA-licensed rabies vaccine,
and dogs and cats overdue for rabies vaccination lacking documentation but
demonstrating an anamnestic response in paired blood samples. (a) In all cases, said quarantine will be under the supervision
of the health commissioner and is to be at the expense of the owner or
harborer. Any signs of illness in the dog, cat, or ferret must be reported
immediately to the health commissioner. (b) The quarantine period will not be for less than forty-five
days. (3) Whenever it is known
by the health commissioner of the health district that any other non-human
mammal has been exposed to rabies, the health commissioner, at his or her
discretion may direct the quarantine or immediate euthanizing of said mammal by
a suitable humane method.
Last updated August 1, 2024 at 7:55 AM
|
Rule 3701-3-30 | Report of suspected rabid mammal.
Effective:
August 1, 2024
Any licensed doctor of veterinary medicine or other
person who examines, treats, owns, harbors, or otherwise cares for any mammal
which exhibits symptoms or behavior suggestive of rabies, are to confine and
isolate such mammal in suitable quarters and will report such fact within
twenty-four hours after the symptoms or behaviors are observed or known to the
health commissioner of the health district wherein such mammal is confined.
Such mammal is to be confined until it has been determined that it is not
afflicted with rabies. If it is determined that the mammal is rabid, the health
commissioner must take such action as is necessary to prevent the occurrence of
rabies in individuals or mammals known or presumed to have been exposed to such
rabid mammal.
Last updated August 1, 2024 at 7:55 AM
|
